In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Revascularisation and quality of life in stable chronic angina patients. Is it a relevant variable? Results from a National Survey

Session Poster session 1

Speaker Xavier Garcia-Moll Marimon

Event : ESC Congress 2017

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease (Chronic)
  • Session type : Poster Session

Authors : X Garcia-Moll Marimon (Barcelona,ES), V Barrios (Madrid,ES), F Marin (Murcia,ES), JJ Alonso (Getafe,ES), X Borras (Barcelona,ES)

Authors:
X. Garcia-Moll Marimon1 , V. Barrios2 , F. Marin3 , J.J. Alonso4 , X. Borras1 , 1Hospital de la Santa Creu i Sant Pau, Department of Cardiology - Barcelona - Spain , 2University Hospital Ramon y Cajal de Madrid, Cardiology - Madrid - Spain , 3Hospital Clínico Univeristario Virgen de la Arrixaca, Cardiology - Murcia - Spain , 4University Hospital of Getafe, Cardiology - Getafe - Spain ,

On behalf: AVANCE II Investigators

Citation:
European Heart Journal ( 2017 ) 38 ( Supplement ), 200

Introduction: Coronary revascularisation has improved during the last decades, both technically and its adjuvant therapy. It is now a safe procedure in patients with suitable coronary anatomy. However, there is little information on quality of life after revascularization and reappearance of anginal symptoms.

Purpose: The aim of this study was to assess reappearance of symptoms after revascularization and its impact on quality of life (QoL) in patients with chronic stable angina (CSA).

Methods: Observational multicentric National survey where 1507 patients with CSA patients were prospectively and consecutively recruited. Baseline characteristics, Seattle Angina Questionnaire (SAQ), SF-12 and Morisky-Green scores were obtained.

Results: 1290 (85.6%) patients had prior revascularization: CABG+PCI 7.2%, CABG 13.9%, PCI 78.9%. Patients with coronary revascularization were more frequently men than women (p=0.001), were younger, had more prior myocardial infarction, less history of hypertension, more DM, less kidney disease, higher hemoglobin, lower LDL-C, higher triglycerides, and better heart rate control. Density of angina was similar in both groups. Revascularized patients were treated less frequently with non-dihydropiridinic CCB, nitrates, trimetazidine, but received more ivabradine, ranolazine, antiplatelet treatment, statins and oral antidiabetic treatment. New symptoms resumed in 31.2% of patients after a median of 12 months from revascularization. There was a trend to a worse Morisky Green score among non revascularized patients. SAQ questionnaire yielded worse results in non revascularized patients in all domains but one (similar perception of disease). Standardized SF12 domains showed an impaired physical component, with similar standardized mental component. However, any significant difference between groups disappeared in the multiple regression analysis.

Conclusions: Coronary revascularization is frequent in patients with chronic stable angina. However, reappearance of angina symptoms in also frequent: 31% of patients had new symptoms after a median of 12 months after coronary revascularization. There is no significant difference in QoL in revascularized patients.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are